Karlijn Hummelink

PD-1T TILs as precision biomarker in NSCLC 61 2 Figure S4. Combination of PD-L1 TPS and PD-L1 IC to predict clinical benefit. (A) Examples of IHC analysis of NSCLC tumors with IC0, IC1, IC2 and IC3 PD-L1 immune cell (IC) score. (B) Correlation of PD-L1 TPS scores and IC scores. The size of the circles indicates the number of tumors. R2 and P-values were calculated using linear regression analysis. (C-D) Sensitivity and specificity of biomarkers PD-L1 TPS at either 50% or 1% cut-off, PD-L1 IC 2, and PD-L1 TPS at either 50% or 1% cut-off plus PD-L1 IC 2 for DC 6m (C) and 12m (D) in all nivolumab treated patients (n=94). Results are compared to PD-1T 90 per mm2 as univariate biomarker.

RkJQdWJsaXNoZXIy MTk4NDMw